Sun Pharma Advanced Research Past Earnings Performance
Past criteria checks 0/6
Sun Pharma Advanced Research's earnings have been declining at an average annual rate of -8.7%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 3.3% per year.
Key information
-8.7%
Earnings growth rate
-5.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 3.3% |
| Return on equity | -109.6% |
| Net Margin | -340.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Sun Pharma Advanced Research makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,067 | -3,634 | 2,787 | 1,372 |
| 30 Sep 23 | 2,239 | -2,536 | 2,783 | 1,443 |
| 30 Jun 23 | 2,343 | -2,356 | 2,544 | 1,534 |
| 31 Mar 23 | 2,388 | -2,226 | 2,390 | 1,495 |
| 31 Dec 22 | 2,163 | -2,116 | 2,157 | 1,247 |
| 30 Sep 22 | 1,474 | -2,376 | 1,844 | 1,187 |
| 30 Jun 22 | 1,437 | -2,244 | 1,803 | 1,170 |
| 31 Mar 22 | 1,372 | -2,034 | 1,658 | 1,084 |
| 31 Dec 21 | 1,401 | -1,891 | 1,526 | 1,129 |
| 30 Sep 21 | 997 | -2,408 | 1,513 | 1,219 |
| 30 Jun 21 | 895 | -2,692 | 1,412 | 1,500 |
| 31 Mar 21 | 2,530 | -1,511 | 1,457 | 1,840 |
| 31 Dec 20 | 2,476 | -1,940 | 1,452 | 2,220 |
| 30 Sep 20 | 2,454 | -1,819 | 1,454 | 2,129 |
| 30 Jun 20 | 2,450 | -1,615 | 1,436 | 1,880 |
| 31 Mar 20 | 768 | -3,124 | 1,355 | 1,689 |
| 31 Dec 19 | 1,389 | -2,222 | 1,263 | 1,566 |
| 30 Sep 19 | 1,392 | -2,357 | 1,320 | 1,707 |
| 30 Jun 19 | 1,834 | -1,751 | 1,319 | 1,614 |
| 31 Mar 19 | 1,829 | -1,454 | 1,371 | 1,479 |
| 31 Dec 18 | 1,181 | -1,336 | 1,035 | 1,050 |
| 30 Sep 18 | 1,177 | -1,226 | 969 | 960 |
| 30 Jun 18 | 717 | -1,826 | 1,015 | 1,064 |
| 31 Mar 18 | 783 | -1,970 | 1,477 | 1,174 |
| 31 Dec 17 | 998 | -2,326 | 962 | 1,623 |
| 30 Sep 17 | 1,034 | -2,405 | 933 | 1,704 |
| 30 Jun 17 | 1,829 | -1,630 | 891 | 1,703 |
| 31 Mar 17 | 1,810 | -1,190 | 844 | 1,366 |
| 31 Dec 16 | 1,827 | -976 | 807 | 1,315 |
| 30 Sep 16 | 1,932 | -723 | 722 | 1,333 |
| 30 Jun 16 | 1,415 | -1,048 | 431 | 980 |
| 31 Mar 16 | 1,613 | -700 | 567 | 1,195 |
| 31 Dec 15 | 1,628 | -698 | 595 | 1,241 |
| 30 Sep 15 | 1,605 | -477 | 576 | 1,056 |
| 30 Jun 15 | 1,633 | -314 | 552 | 1,049 |
| 31 Mar 15 | 1,557 | -395 | 459 | 1,110 |
| 31 Dec 14 | 1,556 | -326 | 465 | 1,005 |
| 30 Sep 14 | 1,873 | 173 | 457 | 818 |
| 30 Jun 14 | 1,672 | 111 | 453 | 719 |
| 31 Mar 14 | 1,670 | 303 | 444 | 527 |
| 31 Dec 13 | 1,963 | 769 | 458 | 441 |
| 30 Sep 13 | 1,376 | 218 | 439 | 452 |
| 30 Jun 13 | 1,166 | 53 | 418 | 411 |
Quality Earnings: 532872 is currently unprofitable.
Growing Profit Margin: 532872 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532872 is unprofitable, and losses have increased over the past 5 years at a rate of 8.7% per year.
Accelerating Growth: Unable to compare 532872's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 532872 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 532872 has a negative Return on Equity (-109.57%), as it is currently unprofitable.